Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

Recursion posts strong cash, detailed trial data, and major pharma milestone payments.

What the company is saying

Recursion frames itself as a leader in AI-driven drug discovery, emphasizing new clinical evidence from its REC-4881 and REC-1245 programs. The company highlights positive Phase 2 results in familial adenomatous polyposis (FAP), with REC-4881 showing high rates of polyp reduction and sustained effects post-treatment. It underscores the scale of the FAP market opportunity at $15 billion and the unmet need among 50,000 patients in the US and EU5. Recursion details progress in its partnerships, noting a $10 million milestone from Sanofi and $144 million in total Sanofi payments, as well as $216 million from Roche and Genentech collaborations. The company presents its financial position as robust, reporting $561.5 million in cash at quarter-end and $748.7 million pro forma after a recent offering, projecting a cash runway into 2029. Leadership changes are also spotlighted, with Fred Hassan appointed Chair of the Board as of October 31, 2026, bringing decades of pharma experience.

What the data suggests

The company’s cash, cash equivalents, and restricted cash were $561.5 million as of September 30, 2026, rising to $748.7 million after a $187.2 million underwritten offering. Total revenue for Q3 2026 was $18.6 million, primarily from collaborations. REC-4881 Phase 2 data show 87% of patients (13/15) had reduced polyp burden after 12 weeks, with a 47% median reduction; about one-third achieved at least 65% reduction. Twelve weeks post-treatment, 85% remained below baseline. Upper GI reductions were seen in 92% of patients, with two achieving ≥98% reduction; lower GI reductions were seen in 82% of patients, with a 50% median reduction. Safety profile was favorable, with no Grade 4/5 adverse events. REC-1245 early data showed a 91.7% disease control rate at 45 mg QD or higher (n=12), with no dose-limiting toxicities. Partnership milestones are significant: $10 million from Sanofi (total $144 million), $216 million from Roche/Genentech, and eligibility for over $300 million in additional milestones per major collaboration. The company projects a cash runway into 2029, but revenue remains modest relative to cash and R&D outlays. Most commercial benefits and pivotal trials are still several years away.

Analysis

The announcement is upbeat, highlighting positive clinical trial data, partnership milestones, and a strong cash position. However, a significant portion of the claims are forward-looking, including the initiation of a registrational trial for REC-4881 in the second half of 2027, anticipated clinical data readouts, and large potential milestone/royalty payments from partnerships. While the Phase 2 data for REC-4881 is detailed and promising, the sample sizes are small and the pivotal trial is at least 18-24 months away, with commercial benefits even further out. The company emphasizes a $15 billion market opportunity and eligibility for over $300 million in future milestones, but these are contingent on successful future development and regulatory approvals. The capital intensity is high, with nearly $750 million in cash and ongoing R&D spend, but no profitability metrics (net income, EBITDA, operating profit) are disclosed, and revenue remains modest relative to R&D outlays. The narrative is somewhat inflated by repeated references to large addressable markets and potential future payments, which are not yet realized.

Risk flags

• ●The majority of clinical and commercial milestones are long-term, with pivotal trials and potential product launches not expected until 2027 or beyond. This exposes the company to multi-year development, regulatory, and competitive risks before any major revenue realization.
• ●Revenue from collaborations ($18.6 million for Q3 2026) is modest compared to cash reserves and projected R&D spend, making the company dependent on continued milestone payments and external funding until products reach market.
• ●The $15 billion market opportunity for FAP and eligibility for over $300 million in future milestones are aspirational and contingent on successful clinical outcomes, regulatory approvals, and partner follow-through, none of which are guaranteed.
• ●Clinical data for REC-4881 and REC-1245 are based on small patient cohorts, which may not be predictive of broader efficacy or safety in larger, more diverse populations. Subsequent trial phases could reveal less favorable results.
• ●Appointment of Fred Hassan as Chair brings deep industry experience, but board leadership alone does not ensure execution or commercial success; personal or institutional involvement does not guarantee investment returns.

Bottom line

Recursion’s Q3 2026 update demonstrates strong liquidity, with $748.7 million pro forma cash and a multi-year runway, and provides granular clinical data supporting its AI-driven pipeline. The company has secured substantial milestone payments from Sanofi and Roche/Genentech, but core revenue remains modest and most commercial inflection points are years away. The clinical results for REC-4881 and REC-1245 are promising but based on limited patient numbers, and pivotal trials are not imminent. The $15 billion FAP market and large milestone eligibility are theoretical until later-stage trials and regulatory approvals are achieved. Fred Hassan’s appointment as Chair adds board-level credibility but does not reduce the long-term execution risks. Investors should focus on the pace of clinical advancement, realization of further milestones, and evidence of broader efficacy as key drivers for future value.

Announcement summary

(NASDAQ:RXRX) Recursion reported financial results for the third quarter ended September 30, 2026, and provided business updates on its clinical, pipeline, and platform progress. The company highlighted positive Phase 2 results from the ongoing TUPELO trial of REC-4881 in familial adenomatous polyposis (FAP), a disease affecting more than 50,000 patients in the US and EU5, representing a potential $15 billion opportunity. Among approximately 35,000 post-colectomy patients, upper GI disease is the area of highest unmet need. After 12 weeks of REC-4881 (4 mg QD), 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction, and about 1 in 3 achieved reductions of at least 65%. Twelve weeks after stopping treatment, 85% of evaluable patients (11 of 13) remained below baseline. Median polyp burden reductions were 55% in the upper GI and 50% in the lower GI after 12 weeks of treatment. In the upper GI, 92% of patients (12 of 13) had reductions after 12 weeks, with two achieving at least 98% reductions; half (6 of 12) improved by at least one Spigelman stage, and 92% (11 of 12) remained below baseline 12 weeks after stopping treatment. In the lower GI, 82% (9 of 11) had reductions after 12 weeks, with a 50% median reduction and 1 in 3 achieving at least 65%; 70% of evaluable patients remained below baseline 12 weeks after stopping treatment. For larger, higher-risk polyps (>5 mm), 6 of 8 patients had fewer after 12 weeks, with four achieving reductions of at least 80%, including two whose counts fell from more than 90 polyps to one. Six of eight remained below baseline 12 weeks after stopping treatment. No new safety signals were observed; 81% (21 of 26) had Grade 1 or 2 treatment-related adverse events (TRAEs), 15% (4 of 26) had Grade 3, and one patient had no TRAEs. No Grade 4 or 5 TRAEs and no additional discontinuations were reported. Recursion anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions. Early data from the Phase 1 dose-escalation portion of DAHLIA, the ongoing Phase 1/2 study of REC-1245, showed three partial responses per RECIST 1.1 criteria (2 confirmed, 1 unconfirmed) in heavily pretreated patients, with a disease control rate of 91.7% at doses of 45 mg QD or higher (n=12). At the 45 mg QD dose (n=10), no dose-limiting toxicities or treatment-related serious adverse events were observed, and the most frequent TRAEs were Grade 1 or 2 fatigue and anemia (30% each). Preliminary dose expansion data in endometrial cancer are expected in the second half of 2027. Recursion initiated the Phase 1/2 ZINNIA clinical study of REC-7735 in the second half of 2026. The company plans to focus resources on high-impact partnerships and internal programs, including REC-4881, REC-1245, REC-4539, REC-7735, and REC-102, and intends to pursue partnership opportunities for REC-617 and REC-3565. Sanofi has optioned the first development candidate from the companies’ collaboration, triggering a $10 million milestone payment to Recursion and bringing total upfront and milestone payments from Sanofi to $144 million. Recursion is eligible for more than $300 million in additional milestones under the Sanofi program, with double-digit royalties on net product sales if approved. Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a previously unexplored neuroscience target. Recursion has achieved $216 million in upfront and milestone payments from the Roche and Genentech collaboration, which includes up to 40 potential small molecule discovery programs, each with the potential for more than $300 million in milestones and tiered royalties up to high single digits per program. Fred Hassan was appointed Chair of the Board, effective October 31, 2026. Cash, cash equivalents, and restricted cash were $561.5 million as of September 30, 2026. Including net proceeds of approximately $187.2 million from an underwritten offering completed on October 16, 2026, pro forma cash was approximately $748.7 million. Based on current operating plans with no additional financing, the company expects its cash runway to extend into 2029. Total revenue was $18.6 million for the third quarter of 2026.

Disagree with this article?